BACKGROUND: Patient outcomes following resection of colorectal liver metastases (CLM)
after second‐line chemotherapy regimen is unknown. METHODS: From August 1998 to …

Background. Metastatic colorectal cancer has a poor prognosis, and the majority of patients
are left with palliative measures. The development seen using medical treatments are …

Biologic agents, specifically epidermal growth factor receptor blockers and vascular
endothelial growth factor inhibitors, combined with cytotoxic agents have become a standard …

Background The treatment of patients with metastatic colorectal cancer (mCRC) has evolved
during the past 2 decades, and patient survival has increased. Consequently, patients are …

Abstract Aim of the Study To describe trends in survival of non-resectable metastatic
colorectal cancer (MCRC) over a 34-year period in a French population-based registry …

Liver resection offers the only chance of cure for patients with advanced colorectal cancer
(CRC). Typically, the 5-year survival rates following liver resection range from 25% to 40 …

Introduction The aim of this study was to evaluate the efficacy and toxicity of molecular
targeted agents plus chemotherapy compared with chemotherapy alone as second-line …

3554 Background: Approximately 30% of patients (pts) diagnosed with colorectal cancer
(CRC) develop liver metastases (LM). Liver is the most common organ of metastasis of CRC …

Colorectal cancer (CRC) is frequently complicated by metastatic disease, with the liver being
the most common site of metastasis. Surgical resection is the only realistic cure for colorectal …

Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer
of the colon-rectum, that by orphan disease, it is now becoming an important paradigm of …